Read more

September 23, 2020
1 min read
Save

Top in endocrinology: Circadian rhythm, zoledronic acid and AF risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The top five stories in endocrinology last week were all based on presentations from the American Society for Bone and Mineral Research virtual meeting.

One presentation was about research that showed circadian rhythm disruption may accelerate aging and drive cardiometabolic disease. Other study data showed that zoledronic acid modestly increases the risk for atrial fibrillation compared with denosumab (Prolia, Amgen) in adults with osteoporosis.

Atrial fibrillation 2019
Source: Adobe Stock

Read these and more top stories in endocrinology below:

Circadian rhythm disruption may accelerate aging, drive cardiometabolic disease

Sleep-wake circadian rhythm is an important mechanism to maintain biological timekeeping, and disruptions from light exposure, dietary challenges and timing of food intake can have cardiometabolic consequences, according to a speaker. Read more.

Zoledronic acid modestly increases atrial fibrillation risk vs. denosumab

Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared with denosumab, according to a study data. Read more.

Zoledronic acid maintains BMD gains after overlapping teriparatide, denosumab treatment

A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral density after 15 months of overlapping teriparatide (Forteo, Eli Lilly; Bonsity, Alvogen) and denosumab therapy, according to a speaker. Read more.

Treatment sequence influences romosozumab effectiveness in osteoporosis

Women with osteoporosis who received romosozumab (Evenity, Amgen) experienced the greatest gains in bone formation when the drug was administered before antiresorptive therapy, according to a speaker. Read more.

Prolonged effects from osteoporotic fractures drive health care, indirect costs

Women who sustain any type of osteoporotic fracture have higher adjusted all-cause health care costs and indirect costs in the 5 years after fracture compared with matched nonfracture controls, according to a speaker. Read more.